Lupin announced today the acquisition of anti-diabetes trademarks GIBTULIO', GIBTULIO MET' and AJADUO' from Boehringer Ingelheim International GmbH (Boehringer Ingelheim), to strengthen its diabetes portfolio in the country.
As per the terms of the agreement, the trademark rights for these brands will be transferred to Lupin by March next year. Lupin has been marketing GIBTULIO' and GIBTULIO MET' since 2016, and AJADUO' since 2018 in the Indian market through existing co-marketing agreements with Boehringer Ingelheim India.
GIBTULIO' (empagliflozin), GIBTULIO MET' (empagliflozin + metformin) and AJADUO' (empagliflozin + linagliptin) belong to a novel class of oral anti-diabetic drug, sodium glucose cotransporter-2 (SGLT-2) inhibitor (and combinations). These are indicated to improve glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise. Empagliflozin is also indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes, and the risk of cardiovascular death and hospitalization for heart failure in adults with chronic kidney disease.
Powered by Capital Market - Live News